Literature DB >> 11238198

Cell-mediated immune response to human papillomavirus infection.

M Scott1, M Nakagawa, A B Moscicki.   

Abstract

Entities:  

Mesh:

Year:  2001        PMID: 11238198      PMCID: PMC96039          DOI: 10.1128/CDLI.8.2.209-220.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


× No keyword cloud information.
  156 in total

Review 1.  Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets.

Authors:  D A Norris
Journal:  J Invest Dermatol       Date:  1990-12       Impact factor: 8.551

Review 2.  Cytokine flow cytometry: understanding cytokine biology at the single-cell level.

Authors:  C Prussin
Journal:  J Clin Immunol       Date:  1997-05       Impact factor: 8.317

3.  Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls.

Authors:  J C Luxton; R C Rose; T Coletart; P Wilson; P S Shepherd
Journal:  J Gen Virol       Date:  1997-04       Impact factor: 3.891

4.  Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease.

Authors:  J M Palefsky; E A Holly; M L Ralston; S P Arthur; C J Hogeboom; T M Darragh
Journal:  Genitourin Med       Date:  1997-06

5.  Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.

Authors:  A S Kadish; G Y Ho; R D Burk; Y Wang; S L Romney; R Ledwidge; R H Angeletti
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

6.  Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles.

Authors:  C Dupuy; D Buzoni-Gatel; A Touze; P Le Cann; D Bout; P Coursaget
Journal:  Microb Pathog       Date:  1997-04       Impact factor: 3.738

7.  Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

Authors:  E M Evans; S Man; A S Evans; L K Borysiewicz
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

8.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

9.  Serum levels of soluble tumor-necrosis-factor receptors in patients with benign and malignant HPV-associated anogenital lesions.

Authors:  M Malejczyk; J Jóźwiak; A Osiecka; P I Roszkowski; W Mazurkiewicz-Smoktunowicz; T T Rogoziński; L Walczak; S Jabłońska; S Majewski; J Malejczyk
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

10.  Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions.

Authors:  H J Bontkes; T D de Gruijl; J M Walboomers; A J van den Muysenberg; A W Gunther; R J Scheper; C J Meijer; J A Kummer
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  77 in total

1.  Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin.

Authors:  Michelle R Iannacone; Wei Wang; Heather G Stockwell; Kathleen O'Rourke; Anna R Giuliano; Vernon K Sondak; Jane L Messina; Richard G Roetzheim; Basil S Cherpelis; Neil A Fenske; Kristina M Michael; Tim Waterboer; Michael Pawlita; Dana E Rollison
Journal:  J Infect Dis       Date:  2012-06-01       Impact factor: 5.226

2.  Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking.

Authors:  Mark E Scott; Yifei Ma; Sepideh Farhat; Stephen Shiboski; Anna-Barbara Moscicki
Journal:  J Clin Immunol       Date:  2006-05-16       Impact factor: 8.317

3.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 4.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 5.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

6.  Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.

Authors:  Mark E Scott; Yurii B Shvetsov; Pamela J Thompson; Brenda Y Hernandez; Xuemei Zhu; Lynne R Wilkens; Jeffrey Killeen; Dien D Vo; Anna-Barbara Moscicki; Marc T Goodman
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

Review 7.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

Review 8.  Early Defensive Mechanisms against Human Papillomavirus Infection.

Authors:  Andrea Moerman-Herzog; Mayumi Nakagawa
Journal:  Clin Vaccine Immunol       Date:  2015-06-10

9.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 10.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.